Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUL321 in Healthy Participants
NCT07760467Phase 1Recruiting
- Sponsor
- The United Laboratories International Holdings
- Start
- Aug 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing TUL321 with Placebo (2 arms). Primary endpoints: Incidence of adverse events up to 17 days and Changes from baseline in physical examinations, vital signs, electrocardiograms (ECG), and laboratory tests up to 17 days. Started Aug 2026; status: recruiting.
02
Drugs
TUL321
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07760467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07760467.